Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 2/20 | 0.68 |
| ▸ | CTH | P32929 | 1/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.62 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.59 |
| ▸ | RRM2 | P31350 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | RRM1 | P23921 | 1/20 | 0.59 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.59 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534248 | 1.00 | TOP2A (0.68) | TOP2ACTHADORA2AHKDC1RRM2 | |
| SCHEMBL31690655 | 0.86 | TOP2A (0.82) | TOP2ACTHADORA2AHKDC1NPC1 | |
| SCHEMBL28284810 | 0.85 | TOP2A (0.52) | TOP2ACTHADORA2AHKDC1RRM2 | |
| SCHEMBL31690665 | 0.84 | TOP2A (0.73) | TOP2ACTHADORA2AHKDC1NPC1 | |
| SCHEMBL13826730 | 0.83 | NPC1 (0.68) | TOP2ACTHNPC1RAB9AMEN1 | |
| SCHEMBL2562208 | 0.83 | TOP2A (0.68) | TOP2ACTHADORA2AHKDC1NPC1 | |
| SCHEMBL14542967 | 0.83 | NPC1 (0.59) | TOP2ACTHADORA2AHKDC1NPC1 | |
| SCHEMBL4100136 | 0.83 | NPC1 (0.59) | TOP2ACTHADORA2AHKDC1NPC1 | |
| SCHEMBL4100134 | 0.83 | NPC1 (0.59) | TOP2ACTHADORA2AHKDC1NPC1 | |
| SCHEMBL2562207 | 0.83 | TOP2A (0.68) | TOP2ACTHADORA2AHKDC1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110698511-B | Tin complex with 2-pyridinecarboxaldehyde thiosemicarbazone as ligand and synthesis method thereof | 广西师范大学 | 2021-09-14 | — | — | CN | claimed |
| US-20210229064-A1 | BRANCHED POLYMER CROSS-LINKED GRAPHENE OXIDE ADSORBENT MATERIAL | DUKE UNIVERSITY | 2021-07-29 | — | — | US | claimed |
| CN-109810128-B | Indium complex with 2-pyridylaldehyde thiosemicarbazone as ligand and synthetic method and application thereof | 广西师范大学 | 2021-04-02 | — | — | CN | claimed |
| CN-112079853-A | Zinc complex with 2-pyridylaldehyde thiosemicarbazone as ligand and synthetic method and application thereof | 广西师范大学 | 2020-12-15 | — | — | CN | claimed |
| CN-110698511-A | Tin complex with 2-pyridinecarboxaldehyde thiosemicarbazone as ligand and synthesis method thereof | 广西师范大学 | 2020-01-17 | — | — | CN | claimed |
| US-7521062-B2 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-04-21 | — | — | US | claimed |
| US-4655885-A | DIRECTLY TRANSFERRING ELECTRONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1987-04-07 | — | — | US | claimed |
| EP-0187719-A2 | Surface-modified electrode and its use in a bioelectrochemical process | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1986-07-16 | — | — | EP | claimed |
| US-12144833-B1 | Copper chelation therapeutics | BERMUDES DAVID GORDON (US) | 2024-11-19 | — | — | US | disclosed |
| CN-118184574-A | Modified polyoxometalate organic-inorganic hydrogel and preparation method and application thereof | 河南大学 | 2024-06-14 | — | — | CN | disclosed |
| EP-4275759-A2 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | Dana-Farber Cancer Institute, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3475688-B1 | ELECTRODE ARRANGEMENT WITH IMPROVED ELECTRON TRANSFER RATES FOR REDOX OF MOLECULES | BOSCH GMBH ROBERT (DE) | 2023-08-09 | — | — | EP | disclosed |
| EP-3515449-B1 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | DANA FARBER CANCER INST INC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-11471497-B1 | Copper chelation therapeutics | BERMUDES DAVID GORDON (US) | 2022-10-18 | — | — | US | disclosed |
| US-6458816-B1 | ANTICANCER AGENTS | VION PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020119955-A1 | Modified prodrug forms of AP/AMP | NANOTHERAPEUTICS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002030424-A1 | MODIFIED PRODRUG FORMS OF AP/AMP | VION PHARMACEUTICALS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| EP-0570294-B1 | 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents | UNIV YALE (US) | 1997-07-30 | — | — | EP | disclosed |
| US-4655885-A | DIRECTLY TRANSFERRING ELECTRONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1987-04-07 | — | — | US | disclosed |
| EP-0187719-A2 | Surface-modified electrode and its use in a bioelectrochemical process | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119955-A1 | Modified prodrug forms of AP/AMP | AP3B1, AP3D1, AP3M1 | TOP2A 2539/4885CTH 2791/4885ADORA2A 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.